Literature DB >> 16172878

[Surgical management of acne inversa].

G Weyandt1.   

Abstract

The pathogenesis of acne inversa is follicular hyperkeratosis with occlusion and rupture. The subsequent acute inflammatory response leads to erythema, abscesses, fistulas, sinus tracts and scarring. Sites of predilection are the intertriginous regions. Many conservative therapies have only a supportive character. Therapy of choice is the early surgical intervention with complete excision of the involved areas, as conservative therapy is at best supportive. Although healing by second intention is preferred, all variations of flaps and grafts have been used. Usually the course of acne inversa lasts years until patients elect surgery after a physical and psychological odyssey.

Entities:  

Mesh:

Year:  2005        PMID: 16172878     DOI: 10.1007/s00105-005-1032-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  23 in total

1.  Finasteride as a therapy for hidradenitis suppurativa.

Authors:  A M Farrell; V A Randall; T Vafaee; R P Dawber
Journal:  Br J Dermatol       Date:  1999-12       Impact factor: 9.302

Review 2.  [Acne inversa (stage 2)].

Authors:  V Wienert; H Breuninger; R P A Müller
Journal:  Hautarzt       Date:  2002-01       Impact factor: 0.751

3.  The pathogenesis of hidradenitis suppurativa in man; experimental and histologic observations.

Authors:  W B SHELLEY; M M CAHN
Journal:  AMA Arch Derm       Date:  1955-12

4.  Hidradenitis and other variants of acne.

Authors:  H A BRUNSTING
Journal:  AMA Arch Derm Syphilol       Date:  1952-03

Review 5.  Acne inversa (alias hidradenitis suppurativa).

Authors:  I Jansen; P Altmeyer; G Piewig
Journal:  J Eur Acad Dermatol Venereol       Date:  2001-11       Impact factor: 6.166

6.  The clinical genetics of hidradenitis suppurativa revisited.

Authors:  J M Von Der Werth; H C Williams; J A Raeburn
Journal:  Br J Dermatol       Date:  2000-05       Impact factor: 9.302

7.  [Acne inversa (hidradenitis suppurativa): early deetection and curative surgery].

Authors:  A Herrmann; K P Preusser; W C Marsch
Journal:  Chirurg       Date:  2000-11       Impact factor: 0.955

8.  Experience with different treatment modules in hidradenitis suppuritiva: a study of 106 cases.

Authors:  A Mandal; J Watson
Journal:  Surgeon       Date:  2005-02       Impact factor: 2.392

9.  Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa.

Authors:  R Rompel; J Petres
Journal:  Dermatol Surg       Date:  2000-07       Impact factor: 3.398

10.  The prevalence of hidradenitis suppurativa and its potential precursor lesions.

Authors:  G B Jemec; M Heidenheim; N H Nielsen
Journal:  J Am Acad Dermatol       Date:  1996-08       Impact factor: 11.527

View more
  5 in total

Review 1.  [Surgical treatment options for hidradenitis suppurativa/acne inversa].

Authors:  L Scholl; S Hessam; S Reitenbach; F G Bechara
Journal:  Hautarzt       Date:  2018-02       Impact factor: 0.751

Review 2.  Surgical Treatment in Hidradenitis Suppurativa.

Authors:  Ratnakar Shukla; Priyanka Karagaiah; Anant Patil; Katherine Farnbach; Alex G Ortega-Loayza; Thrasivoulos Tzellos; Jacek C Szepietowski; Mario Giulini; Hadrian Schepler; Stephan Grabbe; Mohamad Goldust
Journal:  J Clin Med       Date:  2022-04-21       Impact factor: 4.964

3.  [Infiltrating perineal and scrotal inflammation: rare cutaneous manifestation of familial Mediterranean fever or acne inversa?].

Authors:  J Huber; C Lagally; S Buse; G Hatiboglu; T Höfner; C Hach; M Hohenfellner
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

Review 4.  Hidradenitis Suppurativa: Surgical and Postsurgical Management.

Authors:  Marco Manfredini; Federico Garbarino; Laura Bigi; Giovanni Pellacani; Cristina Magnoni
Journal:  Skin Appendage Disord       Date:  2020-05-14

5.  Acne inversa of the scrotum and penis - aggressive urological treatment.

Authors:  Artur Gibas; Marcin Matuszewski; Igor Michajłowski; Kazimierz Krajka
Journal:  Cent European J Urol       Date:  2012-09-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.